BROADWOOD PARTNERS, L.P. (Bradsher Neal C) purchased 0 shares of IMDX (indirect holdings)

BROADWOOD PARTNERS, L.P. purchased 0 indirectly-held shares of Insight Molecular Diagnostics Inc. (IMDX) on 2026-11-17. Filed jointly with BROADWOOD CAPITAL INC (10% owner) and Bradsher Neal C (10% owner).

Original reporting
SEC EDGAR · BROADWOOD PARTNERS, L.P., BROADWOOD CAPITAL INC, Bradsher Neal C
Published Nov 19, 2026, 10:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IMDX
Neutral
medium confidence
Mentioned
$IMDX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMDXNeutralLow
01

Why it matters

This provides incremental ownership information but lacks key trade details (0 shares, price not disclosed), so it is unlikely to drive a decisive repricing without corroborating filings or operational news.

02

Market read

Insider ownership activity is disclosed, but the specific transaction shows 0 shares and no price, making the actionable signal weak.

03

What to watch

The filing states no pre-arranged 10b5-1 plan and reports indirect holdings; traders may want to compare prior Form 4s to determine whether this is a recurring pattern or a one-off reporting artifact.

Relevance 4/10Novelty 5/10Timing: filed 2026-11-19 for a transaction dated 2026-11-17

Background

The article is an SEC Form 4 insider transaction disclosure for Insight Molecular Diagnostics Inc. (IMDX) by Broadwood Partners, L.P., a 10% owner, filed on 2026-11-19.

Company-level read

Ticker impact

$IMDXNeutralMedium confidence
Context

SEC Form 4 shows Insight Molecular Diagnostics (IMDX) has a 10% owner filing an open-market purchase code P with indirect holdings reported.

Expected impact

Likely limited near-term impact as the transaction shows 0 shares and no disclosed price, reducing interpretability.

Evidence & confidence

Form 4 is primary-source, but the specific transaction details here (shares: 0, price not disclosed) weaken the signal strength versus typical buy filings with nonzero share counts and prices.

Market effects

Minimal, this is a single-company insider transaction with no operational or regulatory catalyst.

None indicated.

None indicated.

Counterpoint

A 0-share open-market purchase entry may reflect administrative or plan-related mechanics rather than a meaningful incremental accumulation signal.

Key entities

  • Insight Molecular Diagnostics Inc.

    Company referenced as the Form 4 issuer (IMDX).

  • Broadwood Partners, L.P.

    10% owner filing the Form 4; transaction code P, indirect holdings.

  • Broadwood Capital Inc.

    Co-reporting 10% owner listed in the filing.

  • Bradsher Neal C

    Co-reporting 10% owner listed in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMDXMed

IMDx Reports Third Quarter 2026 Results and Provides Corporate Update

Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMDx Reports Third Quarter 2026 Results and Provides Corporate Update ● Progress with FDA review of GraftAssureDx and its planned response to FDA’s request for additional information ● Initiated enrollment into GALACTIC registry study from UCLA Medical Center ● Reven